2299-PUB: Liraglutide-Based Therapy Attained A1C Target with Little Risk of Hypoglycemia: Optimization by Average Daily Risk Range Measurement

2299-PUB: Liraglutide-Based Therapy Attained A1C Target with Little Risk of Hypoglycemia: Optimization by Average Daily Risk Range Measurement

Objective: Attainment of appropriate A1C target is indispensable to reduce the risk of diabetes complications in type 2 diabetic (T2D) patients. The aim of this study is to evaluate the ability of GLP-1 receptor agonist, liraglutide (Lira), to achieve A1C

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1)
Hauptverfasser: KASHIMA, KOJI, SHIMIZU, HIROYUKI, YAMADA, MASANOBU
Format: Artikel
Sprache:eng
Schlagworte:
Antidiabetics
Blood glucose
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
GLP-1 receptor agonists
Glucose
Glucose monitoring
Hypoglycemia
Injection
Insulin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective: Attainment of appropriate A1C target is indispensable to reduce the risk of diabetes complications in type 2 diabetic (T2D) patients. The aim of this study is to evaluate the ability of GLP-1 receptor agonist, liraglutide (Lira), to achieve A1C
ISSN:0012-1797
1939-327X
DOI:10.2337/db19-2299-PUB